The United Kingdom and the United States have reached a significant trade agreement that will ensure no import taxes on British medicine shipments going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to increase funding on drugs through the NHS. This move guarantees that duties on these crucial products will stay at nothing for a duration of 36 months.
This agreement follows earlier statements to significantly raise duties on patented drug imports, with increases discussed reaching 100%.
"This arrangement between the Britain reinforces the international landscape for innovative medicines and brings long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement said.
Commercial Significance
Pharmaceuticals constitute one of the UK's most significant export categories to the America, which is easily the biggest destination for large companies like GSK and AstraZeneca.
Export figures indicate that in the year prior to the third quarter, the UK shipped pharmaceutical products worth £11.1bn to the US. This figure accounted for a significant portion of total UK exports in that span.
"This deal protects employment, increases investment and facilitates the UK to emerge as a international leader for medical research," a minister remarked.
Specific British Pledges
The pact involves several specific commitments from the UK:
- Higher Cost Ceiling: The UK will raise the price threshold at which it considers new treatments to be prohibitively costly by a quarter.
- Boosted Medicine Funding: There is a target to raise total public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Rebate Cap: The amount pharmaceutical firms must return to the NHS to prevent overspending will be limited at 15%. In the past, repayments were more than 20%.
Broader Context
The deal comes amid a ongoing row between the drug companies and the ministers over medicine costs and NHS adoption.
These tensions were intensified by claims that US patients were charged several times more for the same drugs than people in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or scrapped, while multi-billion-dollar investments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS had to increase expenditure on drugs, noting that its expenditure on drugs had shrunk as a proportion of its total funding over the past decade.
